Cardium Reports on Second Quarter 2008 Highlights and Financial Results
...RIX Phase 2b clinical study and the AWARE Phase 3 clinical study. Dr. Foster has held leadership clinical development and medical affairs positions at reata Pharmaceuticals, IDEC Pharmaceuticals Corporation, Biogen Idec and Alpha Therapeutic and also has experience in the medical device arena, previously h...Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer
...ntion and treatment of cancer," by researchers and reata scientific collaborators from the Dartmouth Medica...it for patients with cancer and other diseases." reata in-licensed the complete series of Synthetic Trite...ors (for example, TNF and VEGF) at very low doses. reata is also advancing a second Synthetic Triterpenoid ...RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
...Care in Cancer (MASSC) in St Gallen, Switzerland. reata scientists and collaborators presented data showin...matory, and neurodegenerative indications. About reata reata Pharmaceuticals, Inc. is a biopharmaceutical compa...Plant-derived molecules, genetic manipulation point to future chemoprevention methods
...a postdoctoral fellow, and her colleagues found that the triterpenoid CDDO-MA, currently undergoing trails for leukemia and solid tumors (sponsored by reata Pharmaceuticals), significantly reduced the number and sizes of tumors in mice. In addition, a chemically related drug developed by Ligand Pharmaceuti...2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
...e show kicks off on Sunday, September 13 and ends Wednesday, September 16. Additional speakers include BioMarin Pharmaceuticals, Array BioPharma, reata Pharmaceuticals, Proteolix, Novalar Pharmaceuticals, Lexicon Pharmaceuticals, Orexigen Therapeutics, Targacept, Helsinn Therapeutics, OSI Prosidion, N...